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Tanshinone IIA and cryptotanshinone are two pharmacologically active diterpenoids extracted
from the roots of Salvia milthiorriza Bunge, a plant used in Chinese traditional medicine for the
treatment of some cardiovascular and cerebrovascular disease. Until now, the molecular
mechanisms of action of these two diterpenoids on platelets are partially known. To clarify this
aspect, here we utilized an integrated study of pharmacology and computational analysis.
Our results demonstrate that cryptotanshinone is able to inhibit in a concentration dependent
manner the rat platelet aggregation and also is endowed of Gi-coupled P2Y12 receptor antagonist
as demonstrated by docking studies. This computational method was also performed for
tanshinone IIA demonstrating even for this diterpenoid an interaction with the same receptor.
The findings from our study enable a better understanding of tanshinone IIA and cryptotanshinone
biological properties, which could ultimately lead to the development of novel pharmaceutical
strategies for the treatment and/or prevention of some cardiovascular disease.
© 2014 Elsevier B.V. All rights reserved.
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1. Introduction
It is well known that adenosine diphosphate (ADP) plays a
key role in platelet activation. Aberrant activation of platelets
by pathological factors is commonly associated with vascular
disease and thrombosis [1]. ADP activates platelets through two
G-protein coupled receptors, the Gq-coupled P2Y1 receptor and
Gi-coupled P2Y12 receptor [2]. These receptors are targets for
common anti-platelet agents such as aspirin and clopidogrel
[3]. However, the chronic use of these agents is limited because
they can induce resistance or adverse effects on gastrointestinal
tract [4] and, as often happens, drug toxicity may be increased
when multiple antiplatelet drugs are used. In this context, new
antiplatelet agents are greatly needed to increase the efficacy
and reduce side effects. Nowadays, an increasing number of
studies have been performed to search new agents from
natural source and it is well know that some phytochemicals
from plants have generated new drugs [5–7].
Tanshinone IIA (TIIA, 1 in Fig. 1), from roots of Salvia
milthiorriza Bunge (Lamiaceae) (also known as danshen), is an
example of diterpenoid, studied in vitro and in vivo, able to
inhibit platelet aggregation and to induce an increase of blood
viscosity. We have previously demonstrated that these effects
are mediated via the modulation of tubulin acetylation and
inhibition of Erk-2 phosphorylation [8]. In our continuing
studies on pharmacology of danshen constituents, here we
explored the effect of cryptotanshinone (CRY, 2 in Fig. 1),
another major lipophilic constituent present in danshen, on
platelet aggregation [9–11].
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To this aim, we have tested in vitro the potential
antiaggregant effect of 2 and simultaneously the interac-
tion of 1 and 2 on the purinergic platelet receptor by a
computational analysis.
2. Results and discussion
Tanshinone IIA (1), one of the lipophilic constituents
present in danshen, is able to inhibit platelet aggregation and
to induce an increase of blood viscosity via the modulation of
tubulin acetylation and inhibition of Erk-2 phosphorylation [8].
Here, we expand our previous observations and, by amolecular
docking study, we investigated the interaction of 1 with the
binding site of G-protein-coupled purinergic receptors P2Y12R
(PDB code: 4NTJ) [12] using AutodockVina software [13].
P2Y12R, is a target for the development of novel anti-platelet
therapies being involved in the regulation of the platelet
activation and thrombus formation [14,15]. In particular, in
order to rationalize the binding mode of 1, we have used
the crystal structure of P2Y12R in complex with ethyl 6-
(4-((benzysulphonyl)carbamoyl)piperidin-l-yl)-5-cyano-
2-methylnicotinate non-nucleotide antagonist (AZD1283, 3
in Fig. 1) [12] as model receptor for our docking studies.
As already reported [12], 3, a potent antagonist of the P2Y12,
makes a number of polar and hydrophobic contacts in the
pocket 1 with side chains of amino-acids of the helices III–VII,
mainly interacting with TYR105, PHE252, ARG256, TYR259,
LEU276 and LYS280 (Fig. 2), and adopting a different orientation
with respect to the agonist [16]. On this basis, we have analyzed
the binding mode of 1 in the P2Y12R in comparison with the
co-crystallized antagonist 3. From the analysis of this docking
studies, even if 1 occupies the pocket 1 (helices III, IV and V), in
analogy to the 3, accounting for its antagonist activity, it poorly
interacts with helices VI and VII (Fig. 3) due to its smaller size
compared to 3 (Figs. 2 and 3).
In more details, 1 shows polar interactions with ASN159,
ASN191 and ARG256, and it makes hydrophobic contacts with
VAL102, PHE252, ARG256 and LYS280. Furthermore, 1 estab-
lishes aweak hydrogen bond between oxygen at position 11 and
the side chain of CYS194, and it forms π–π interactions with the
side chains of TYR105, as observed for 3, and of TYR109 (Fig. 3).
In our continuing studies on pharmacology of danshen
constituents, here we also explored the effect of 2, another
major lipophilic constituent present in danshen, on platelet
aggregation.
Fig. 1.Molecular structure of tanshinone IIA (1), cryptotanshinone (2) and AZD1283 (3).
Fig. 2. 3D model of tanshinone IIA (colored by blue sticks) and AZD1283
(colored by fuchsia sticks) in the antagonist binding site of P2Y12R (PDB code:
4NTJ).
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Fig. 4 shows a concentration-dependent inhibition of re-
versible platelet aggregation expressed as % of inhibition of AUC
(Fig. 4A) or amplitude (Fig. 4B) induced by 2 (0.5, 5 and 50 μM)
added 1 min before the addition of ADP (3 μM). 2 at a con-
centration of 50 μMdisplayed themaximum inhibitory activity
in terms of inhibition of AUC (66.30 ± 14.11%; P b 0.01) and
amplitude (31.00 ± 7.09 %; P b 0.01).
Moreover, considering the structural similarity of the 2
with 1 and its biological activity reported above, we have
performed molecular docking studies of 2 with the P2Y12R
receptor (Fig. 5). Cryptotanshinone shows the same polar
interactions and hydrophobic interactions of 1 in the P2Y12R
binding site interacting with helices III, IV and V, and it
displays an additional hydrophobic interaction with VAL190
(Fig. 6), accounting for the predicted similar energy of
binding. The absence of the double bond at position 17 in 2,
in fact, does not affect its binding with P2Y12R with respect
to 1, and according with the biological data, our docking
results confirm its antiaggregant activity.
3. Concluding remarks
In conclusion, even if tanshinone IIA and cryptotanshinone
show a relatively simple skeleton in comparison to the AZD1283,
our docking results suggest that their established interactions
with P2Y12R are sufficient to rationalize the P2Y12R antagonist
activity of these two diterpenoids. The findings from our study
enable a better understanding of 1 and 2 biological properties,
which could ultimately lead to the development of novel
pharmaceutical strategies for the treatment and/or prevention
of some cardiovascular disease.
Furthermore, the tanshinones, such as tanshinone IIA and
cryptotanshinone, and their derivatives, in fact, could be
utilizable as lead compounds for future cancer and anti-
inflammatory active molecules [17], being able to inhibit the
growth and proliferation of cancer cells, to induce cell cycle
arrest and apoptosis, and to inhibit angiogenesis.
Indeed, tanshinone IIA shows both in vitro and in vivo
biological effects comparable to those of pan-inhibitors, such as
curcumin and oridonin, and interestingly, it interferes with the
pathway of biosynthesis of PGE2, in particular with the COX2
Fig. 3. 3D model of tanshinone IIA (colored by atom types: C blue, O red) into
P2Y12R binding site. Residues in the active site (pocket 1) are represented in
sticks and balls (colored by atom types: C gray, N blue, O red, Hwhite, S yellow).
Fig. 4. Concentration dependent effect of cryptotanshinone (2) on ADP-induced
platelet aggregation. Rat PRPwere incubatedwith 2 (0.5–50 μM) for 1min, and
then exposed to ADP (3 μM) to induce platelet aggregation. Percent (%)
inhibition of aggregation was expressed in terms of AUC (A) or amplitude (B)
calculated as the difference between the maximum value of aggregation in
presence of ADP plus vehicle and the value obtained in thepresence of ADP plus
2. Data are expressed asmean± SEM. *P b 0.05 vs vehicle; **P b 0.01 vs vehicle
(one way ANOVA; n= 7).
Fig. 5. 3D model of tanshinone IIA (colored by blue sticks), AZD1283 (colored
by fuchsia sticks), and tanshinone IIA (colored by blue sticks) into P2Y12R
binding site.
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receptor [17,18]. On these bases, here we suggest the possible
interaction of 1, in analogy with 2 (See Supporting Information),
with themicrosomial prostaglandin E2 synthase (mPGES-1). The
inhibition, in fact, of these two diterpenoids on PGE2 production
by mPGES-1, could suggest a potential association of their anti-
inflammatory and antiplatelet activity.
4. Experimental
4.1. Animals
Male Wistar rats (250–300 g; Harlan Nossan, Correzzana,
Milan, Italy) were used for all the experiments. Animals were
kept under standard conditions, with food andwater ad libitum
and maintained in a 12 h/12 h light/dark cycle at 22 ± 1 °C. All
the in vivo procedures were in accordance with the Italian
legislative decree (D.L.) no. 116 of January 27, 1992 and
associates European Community guidelines (EEC Directive of
1986; 86/609/EEC). All efforts were made to minimize animal
suffering and to reduce their number.
4.2. Chemicals
Cryptotanshinone (≥97%, HPLC), adenosine diphosphate
(ADP) and dimethyl sulfoxide (DMSO) were obtained from
Sigma-Aldrich Co. (Milan, Italy). Unless otherwise stated, all the
other reagents were from Carlo Erba Reagents (Milan, Italy).
4.3. In vitro platelet aggregation assay
In vitro platelet aggregation was measured according to
the turbidimetric method, using two-channel aggregometer
(Chrono-Log, Corporation, Mod. 490, USA). Blood anticoagu-
lated with 3.2% sodium citrate (1:9 citrate/blood, v/v) was
withdrawn frommaleWistar rats (anesthetized by enflurane) by
cardiac puncture. Platelet-rich plasma (PRP) and platelet-poor
plasma (PPP) were prepared as previously described [6,8].
Briefly, PRP was obtained by centrifugation at 800 rpm for
15 min at 25 °C. PPP was prepared from the precipitated
fraction of PRP by centrifugation at 2000 rpm for 20 min at
25 °C. PRP was adjusted to 3 × 108 platelets/ml. Next, 250 μl
of PRP was incubated at 37 °C for 1 min in the cuvette with
20 μl of 2 solution at a final concentration of 0.5, 5 and 50 μM.
Cryptotanshinone-vehicle (0.3% DMSO in distilled water)
was used as control. After incubation, platelet aggregation
was induced by the addition of 20 μl ADP (3 μM). The
maximum platelet aggregation rate was recorded within
10 min with continuous stirring at 37 °C. The light trans-
mittance was calibrated with PPP. The percentage (%) of
inhibition of platelet aggregation was calculated by the
following formula: [(X− Y)/X] × 100%. Xwas the maximum
aggregation rate of vehicle-treated PRP; Ywas themaximum
aggregation rate of sample-treated PRP and was expressed
in terms of AUC (% of total response duration from reagent
addition).
4.4. Computational methods
The chemical structures of tanshinone IIA and
cryptotanshinone were built with Maestro (version 9.6)
[19] and processed with LigPrep version 2.8 [19], generat-
ing all the possible tautomers, protonation states at a pH of
7.4 ± 1.0; and finally minimized using OPLS 2005 force
field. For the subsequent docking calculations, the struc-
tures were converted in the .pdbqt format using Autodock
Tools 1.5.6, adding Gasteiger charges. The three-dimensional
structure of protein target (PDB code: 4NTJ) was prepared
with the Schrödinger Protein Preparation Wizard [19].
Protein .pdb file obtained was then processed with Autodock
Tools 1.5.6 and converted in .pdbqt format, merging non
polar hydrogens and adding Gasteiger charges. Charge
deficit was spread over all atoms of related residues. We
Fig. 6. (A) 3Dmodel of cryptotanshinone (colored by atom types: C green, O red) in the binding site of P2Y12R. Residues in the active site are represented in sticks and
balls (colored by atom types: C gray, N blue, O red, H white). (B) 2D panel representing the interactions between cryptotanshinone and residues in P2Y12R binding site
(charged residues are colored in violet, polar residues are colored in light blue, and hydrophobic residues are colored in green).
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chose coordinates and dimensions along x, y, and z axes of
the grid related to the site of presumed pharmacological
interest. In particular, we chose the binding site between III
and VII chains, and a grid box size of 28 × 28 × 28 and
centered at 17.036(x), 96.731(y), and 50.379(z) was set,
with a spacing of 1.0 Å between the grid points. Molecular
docking study of these two compounds on P2Y12R was
performed using Autodock Vina [13]. The exhaustiveness
value was set to 62, saving 30 conformations as maximum
number of binding modes. Autodock Vina results were
analyzed with Autodock Tools 1.5.6. Illustrations of the 3D
models were generated using Autodock Tools 1.5.6 and
Maestro software [19].
4.5. Statistical analysis
All assays were repeated at least in triplicate and the results
were expressed as mean ± standard error of mean (SEM).
Results were analyzed with one way analysis of variance
(ANOVA), followed by Bonferroni's test for multiple compar-
isons. In some cases, one sample t-test was used to evaluate
significance against the hypothetical zero value. The analysis
was performed using GraphPad Prism Software version 4.0.
P values less than 0.05 were considered significant.
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